[
  {
    "ts": null,
    "headline": "Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine",
    "summary": "Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational ...",
    "url": "https://finnhub.io/api/news?id=6052b7d3be7e69ff8637ce72f555e7e7fdaaee4c2971c309689583e5284c8381",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767614400,
      "headline": "Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine",
      "id": 137991707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational ...",
      "url": "https://finnhub.io/api/news?id=6052b7d3be7e69ff8637ce72f555e7e7fdaaee4c2971c309689583e5284c8381"
    }
  },
  {
    "ts": null,
    "headline": "Moderna, searching for a rebound, to seek approval of mRNA flu shot",
    "summary": "The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.",
    "url": "https://finnhub.io/api/news?id=d16362a38d96ae575eeebd4ed81e46b6de858cd5b3d045d27a8c46e579a51b65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767613440,
      "headline": "Moderna, searching for a rebound, to seek approval of mRNA flu shot",
      "id": 137992567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.",
      "url": "https://finnhub.io/api/news?id=d16362a38d96ae575eeebd4ed81e46b6de858cd5b3d045d27a8c46e579a51b65"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
    "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
    "url": "https://finnhub.io/api/news?id=360f31e2679faa10cbfe8b2a7d1bff7ffefb62476fcd5c9a34e110a65db82b8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767579074,
      "headline": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
      "id": 137987304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
      "url": "https://finnhub.io/api/news?id=360f31e2679faa10cbfe8b2a7d1bff7ffefb62476fcd5c9a34e110a65db82b8e"
    }
  }
]